Is The Hep C Drug Pipeline Beginning To Crack? [View article]
"11:48 AM Deutsche Bank defends Gilead (GILD -1.6%) in the wake of the FDA's halting of Phase II clinical trials for Idenix's drug IDX184 over safety concerns, saying it's a buying opportunity. The firm says the concern is with non-quanosine nukes, and notes Gilead's GS 7977 is a pyrimidine based nuke. It reiterates its Buy rating with a $68 price target. "
Is The Hep C Drug Pipeline Beginning To Crack? [View article]